263 related articles for article (PubMed ID: 37370117)
1. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer.
Katzenellenbogen BS; Guillen VS; Katzenellenbogen JA
Breast Cancer Res; 2023 Jun; 25(1):76. PubMed ID: 37370117
[TBL] [Abstract][Full Text] [Related]
2. Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs.
Guillen VS; Ziegler Y; Gopinath C; Kumar S; Dey P; Plotner BN; Dawson NZ; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
Breast Cancer Res Treat; 2023 Apr; 198(3):607-621. PubMed ID: 36847915
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
[TBL] [Abstract][Full Text] [Related]
5. Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
Cınar V; Hamurcu Z; Guler A; Nurdinov N; Ozpolat B
Breast Cancer; 2022 Nov; 29(6):1106-1120. PubMed ID: 36006564
[TBL] [Abstract][Full Text] [Related]
6. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
[TBL] [Abstract][Full Text] [Related]
7. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
8. HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1.
Zanin R; Pegoraro S; Ros G; Ciani Y; Piazza S; Bossi F; Bulla R; Zennaro C; Tonon F; Lazarevic D; Stupka E; Sgarra R; Manfioletti G
J Exp Clin Cancer Res; 2019 Jul; 38(1):313. PubMed ID: 31311575
[TBL] [Abstract][Full Text] [Related]
9. FOXM1 plays a role in autophagy by transcriptionally regulating Beclin-1 and LC3 genes in human triple-negative breast cancer cells.
Hamurcu Z; Delibaşı N; Nalbantoglu U; Sener EF; Nurdinov N; Tascı B; Taheri S; Özkul Y; Donmez-Altuntas H; Canatan H; Ozpolat B
J Mol Med (Berl); 2019 Apr; 97(4):491-508. PubMed ID: 30729279
[TBL] [Abstract][Full Text] [Related]
10. Identification of FOXM1 as a specific marker for triple‑negative breast cancer.
Tan Y; Wang Q; Xie Y; Qiao X; Zhang S; Wang Y; Yang Y; Zhang B
Int J Oncol; 2019 Jan; 54(1):87-97. PubMed ID: 30365046
[TBL] [Abstract][Full Text] [Related]
11. YTHDC1-dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple-negative breast cancer.
Shen X; Zhong J; Yu P; Liu F; Peng H; Chen N
Cancer Sci; 2024 Jun; 115(6):1881-1895. PubMed ID: 38566554
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA profiling identifies Forkhead box transcription factor M1 (FOXM1) regulated miR-186 and miR-200b alterations in triple negative breast cancer.
Hamurcu Z; Sener EF; Taheri S; Nalbantoglu U; Kokcu ND; Tahtasakal R; Cınar V; Guler A; Ozkul Y; Dönmez-Altuntas H; Ozpolat B
Cell Signal; 2021 Jul; 83():109979. PubMed ID: 33744419
[TBL] [Abstract][Full Text] [Related]
13. Targeting forkhead box M1 transcription factor in breast cancer.
O'Regan RM; Nahta R
Biochem Pharmacol; 2018 Aug; 154():407-413. PubMed ID: 29859987
[TBL] [Abstract][Full Text] [Related]
14. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
[No Abstract] [Full Text] [Related]
15. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
[TBL] [Abstract][Full Text] [Related]
16. FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.
Yau C; Meyer L; Benz S; Vaske C; Scott G; Egan B; Labhart P; Pourmand N; Benz CC
Breast Cancer Res Treat; 2015 Nov; 154(1):23-32. PubMed ID: 26456572
[TBL] [Abstract][Full Text] [Related]
17. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.
Francis RE; Myatt SS; Krol J; Hartman J; Peck B; McGovern UB; Wang J; Guest SK; Filipovic A; Gojis O; Palmieri C; Peston D; Shousha S; Yu Q; Sicinski P; Coombes RC; Lam EW
Int J Oncol; 2009 Jul; 35(1):57-68. PubMed ID: 19513552
[TBL] [Abstract][Full Text] [Related]
18. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
[TBL] [Abstract][Full Text] [Related]
19. FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway.
Yu G; Zhou A; Xue J; Huang C; Zhang X; Kang SH; Chiu WT; Tan C; Xie K; Wang J; Huang S
Oncotarget; 2015 May; 6(13):11281-94. PubMed ID: 25869208
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of forkhead box M1 is associated with aggressive phenotype and poor prognosis in estrogen receptor-positive breast cancer.
Ahn H; Sim J; Abdul R; Chung MS; Paik SS; Oh YH; Park CK; Jang K
J Korean Med Sci; 2015 Apr; 30(4):390-7. PubMed ID: 25829806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
